Reviparin

Reviparin is an antithrombotic and belongs to the group of low molecular weight heparins.

Reviparin

2-Propenoic acid, 3-phenyl-; Kyselina skoricove; Phenylacrylic acid; Beta-Phenylacrylic acid; 2-Propenoicacid, 3-phenyl

Clivarine, Clivarine-MDV

3-phenylprop-2-enoic acid

NA

NA

SC- 0.25ml daily at least 2 hrs prior to surgery.

Used in the prevention and treatment of venous thromboembolism (deep vein thrombosis and pulmonary embolism) and in the treatment of myocardial infarction.

Vomiting, constipation, epistaxis, mucosa, conjunctivitis, asthma, rhinitis, thrombosis; Bleeding from skin, melena; thromboembolism; consumption coagulopathy; petechiae; purpura; pruritus, urticaria; nausea, headache, fever, body pain, GI tract, dyspnoea and hypotension; transient alopoecia, hyperkalaemia, Inj site necrosis; hypoaldosteronism; metabolic acidosis; priapism.

• Nitroglycerin infusion may diminish reviparin effect.
• May displace propranolol from protein-binding sites.
• Increased risk of haemorrhage when used with aspirin.
• Increased risk of hyperkalaemia when used with ACE inhibitors or angiotensin II receptor antagonists.
• Serious GI bleeding may occur when used with ketorolac.

• Blood disorders, cerebrovascular disorders, thrombocytopaenia, severe hypertension, peptic ulcer disease, bacterial endocarditis, oesophageal varices, patients who have recently undergone surgery, severe renal or hepatic impairment. IM admin.
• Patients who have developed thrombocytopenia with heparin.
• Patients with prosthetic heart valves.

Store it at room temperature.

Molecular weight

148.161 g/mol

Molecular formula

C9H8O2

CAS number

9041-08-1

Precautions

• Elderly (women in particular); lactation; children; renal failure; diabetes mellitus.
• Before and during reviparin therapy done platelet count.